Table 1 Baseline characteristics

Disease

Primary disease

53 (47.7%)

10 (47.6%)

43 (47.8%)

0.990 ^B)

Recurrent disease**

58 (52.3%)

11 (52.4%)

47 (52.2%)

Recurrent disease: time since diagnosis

Months

40.9 ± 44.2

51.7 ± 70

38.3 ± 36.3

0.960 ^A)

Initial/actual FIGO stage^C)

FIGO IIa

1 (0.9%)

1 (4.8%)

0 (0%)

0.638 ^A)

FIGO IIc

4 (3.6%)

2 (9.5%)

2 (2.2%)

FIGO IIIa

1 (0.9%)

0 (0.0%)

1 (1.1%)

FIGO IIIb

11 (9.9%)

2 (9.5%)

9 (10.0%)

FIGO IIIc

72 (64.9%)

11 (52.4%)

61 (67.8%)

FIGO IV

22 (19.8%)

5 (23.8%)

17 (18.9%)

Age at operation

Years

63.8 ± 12.1

58.9 ± 11.4

65.0 ± 12.0

0.064 ^A)

Hospitalization time

Days

28.5 ± 14.3

32.9 ± 18.2

27.5 ± 13.1

0.292 ^A)

Body mass index

kg/m²

25.3 ± 5.9

25.7 ± 4.7

25.1 ± 6.2

0.441 ^A)

Follow-up, survivors

Months

35.6 ± 35.3

29.4 ± 15.4

38.3 ± 40.9

0.824 ^A)

ASA stage ^D)

I

1 (0.9%)

0 (0.0%)

1 (1.1%)

0.103 ^A)

II

71 (64.0%)

17 (81.0%)

54 (60.0%)

III

38 (34.2%)

4 (19.0%)

34 (37.8%)

IV

1 (0.9%)

0 (0.0%)

1 (1.1%)

Initial grading

G1

7 (6.3%)

3 (14.3%)

4 (4.4%)

0.414 ^A)

G2

30 (27.0%)

5 (23.8%)

25 (27.8%)

G3

65 (58.6%)

13 (61.9%)

52 (57.8%)

G4

3 (2.7%)

0 (0.0%)

3 (3.3%)

GX

1 (0.9%)

0 (0.0%)

1 (1.1%)

Initial tumor growth pattern

Serous

87 (78.4%)

16 (76.2%)

71 (78.9%)

0.484 ^B)

Mucinous

2 (1.8%)

1 (4.8%)

1 (1.1%)

Endometrioid

10 (9.0%)

3 (14.3%)

7 (7.8%)

Clear cell

2 (1.8%)

0 (0.0%)

2 (2.2%)

Other

4 (3.6%)

0 (0.0%)

4 (4.4%)

Concomitant radiation

4 (3.6%)

0 (0.0%)

4 (4.4%)

0.325 ^B)

Concomitant chemotherapy

Total

75 (67.6%)

14 (66.7%)

61 (67.8%)

0.922 ^B)

Carboplatin

56 (50.5%)

13 (61.9%)

43 (47.8%)

0.244 ^B)

Taxol

14 (12.6%)

4 (19.0%)

10 (11.1%)

0.324 ^B)

Endoxan

4 (3.6%)

0 (0.0%)

4 (4.4%)

0.325 ^B)

Other

20 (18.0%)

2 (9.5%)

18 (20.0%)

0.216 ^B)